PedAM
Pediatric Disease Annotations & Medicines
| Disease | astrocytoma |
| Phenotype | |tuberous sclerosis |
| Sentences | 61 |
| PubMedID- 23567018 | Long-term effect of everolimus on epilepsy and growth in children under 3 years of age treated for subependymal giant cell astrocytoma associated with tuberous sclerosis complex. |
| PubMedID- 22805244 | Everolimus for tumor recurrence after surgical resection for subependymal giant cell astrocytoma associated with tuberous sclerosis complex. |
| PubMedID- 23717811 | Temsirolimus was fda-approved to treat mantle cell lymphoma (samad and younes, 2010), and everolimus was initially approved to treat renal carcinoma in 2009 (motzer et al., 2008), as well as subependymal giant cell astrocytomas (segas) in patients with tuberous sclerosis (tsc; see below) (krueger et al., 2010). |
| PubMedID- 22647206 | Areas covered: the objective of this review is to discuss the history of key findings and innovative cancer research undertaken to successfully develop everolimus as an oncology therapy (afinitor) now approved for patients with advanced renal cell carcinoma (rcc) and for subependymal giant cell astrocytomas (segas) associated with tuberous sclerosis. |
| PubMedID- 24192699 | Equally important avenues of molecular investigation might include inhibiting disease-causing pathways, such as the proposed use of rapamycin for subependymal giant cell astrocytomas in children with tuberous sclerosis;(83) upregulating affected proteins from homologous genes as in models of spinal muscular atrophy (84); or counteracting the downstream effects of a deficient protein, such as the proposed use of igf1 in children with duchenne’s dystrophy [for review, please see liew, 2012 (85)]. |
| PubMedID- 24667738 | This analysis focuses on the clinical presentation, management, and associated burden of subependymal giant cell astrocytomas in patients with tuberous sclerosis complex in the united states. |
| PubMedID- 23404211 | It is approved for the treatment of patients with progressive neuroendocrine tumors of pancreatic origin, advanced renal cell carcinoma, and subependymal giant cell astrocytoma associated with tuberous sclerosis [12]. |
| PubMedID- 24056156 | Specific inhibitors of this pathway have been shown to reduce the volume of subependymal giant cell astrocytomas associated with tuberous sclerosis. |
| PubMedID- 23582393 | Everolimus for astrocytomas in tuberous sclerosis - author's reply. |
| PubMedID- 22136276 | Everolimus: in patients with subependymal giant cell astrocytoma associated with tuberous sclerosis complex. |
| PubMedID- 23203037 | As a result, the united states food and drug administration has approved several rapamycin (sirolimus) and rapamycin derivative compounds (“rapalogs”) for the treatment of nervous system cancers that include subependymal giant cell astrocytoma associated with tuberous sclerosis (everolimus) and neuroendocrine pancreatic tumors (everolimus) [73,99]. |
| PubMedID- 23736025 | Everolimus (afinitor, novartis pharmaceuticals, east hanover, nj, usa) is currently approved by the food and drug administration (fda) for the treatment of several malignancies including advanced renal cell carcinoma (rcc; motzer et al, 2008, 2010), progressive pancreatic neuroendocrine tumours (pnet; yao et al, 2011), subependymal giant cell astrocytomas associated with tuberous sclerosis (krueger et al, 2010) and most recently in combination with exemestane for advanced hormone receptor-positive, her-2-negative breast cancer (baselga et al, 2012). |
| PubMedID- 23158521 | Everolimus for astrocytomas in tuberous sclerosis complex. |
| PubMedID- 23548133 | Down-regulation of mtor kinase by everolimus has been successfully used for the therapy of subependymal giant-cell astrocytomas in patients with tuberous sclerosis. |
| PubMedID- 25456370 | Everolimus for subependymal giant cell astrocytoma in patients with tuberous sclerosis complex: 2-year open-label extension of the randomised exist-1 study. |
| PubMedID- 23686401 | Everolimus received subsequent approval from the fda for the treatment of advanced pancreatic neuroendocrine tumors that are unresectable, locally advanced, or metastatic and for the treatment of subependymal giant cell astrocytoma associated with tuberous sclerosis complex in patients who require therapeutic intervention but are not amenable to surgery [22]. |
| PubMedID- 22654497 | Aggressive retinal astrocytoma associated with tuberous sclerosis complex is a rare variant of this usually benign astrocytoma, and the tumor enlarges progressively, leading to complications, including exudative retinal detachment, vitreous hemorrhage, and neovascular glaucoma.1,2 it has been reported that aggressive retinal astrocytoma can be treated with laser photocoagulation, photodynamic therapy, or intravitreal bevacizumab injection.2–7 herein, we report the case of a patient with aggressive retinal astrocytoma and macular edema who was initially treated with intravitreal bevacizumab injection. |
| PubMedID- 24708766 | The rapamycin analogs cci-779 (temsirolimus) and rad001 (everolimus) are approved for the clinical treatment of advanced renal cell carcinoma [28], progressive neuroendocrine tumors of pancreatic origin [29], subependymal giant cell astrocytoma associated with tuberous sclerosis [30], and more recently for postmenopausal women with advanced hormone receptor-positive, her2-negative breast cancer in combination with the aromatase inhibitor exemestane [31]. |
| PubMedID- 26137524 | Everolimus has since also been fda-approved for neuroendocrine tumors of pancreatic origin (pnet), breast carcinoma, and subependymal giant cell astrocytomas (sega) associated with tuberous sclerosis. |
| PubMedID- 25557360 | Factors affecting response to everolimus therapy for subependymal giant cell astrocytomas associated with tuberous sclerosis. |
| PubMedID- 20422196 | The diagnosis and treatment of subependymal giant cell astrocytoma combined with tuberous sclerosis. |
| PubMedID- 25682485 | Conclusion: everolimus is a promising pharmacological approach to treat clinically significant inoperable cardiac rhabdomyomas or subependymal giant cell astrocytoma associated with tuberous sclerosis complex during the neonatal period. |
| PubMedID- 26381530 | Objective: to analyze the cumulative efficacy and safety of everolimus in treating subependymal giant cell astrocytomas (sega) associated with tuberous sclerosis complex (tsc) from an open-label phase ii study (nct00411619). |
| PubMedID- 25677876 | Reports of high grade astrocytic neoplasms arising in patients with tuberous sclerosis are rare. |
| PubMedID- 22234227 | Hemorrhagic subependymal giant cell astrocytoma in a patient with tuberous sclerosis: case report and review of the literature. |
| PubMedID- 23158522 | Interpretation: these results support the use of everolimus for subependymal giant cell astrocytomas associated with tuberous sclerosis. |
| PubMedID- 25493579 | [subependymal giant cell astrocytoma associated with tuberous sclerosis complex - pharmacological treatment using mtor inhibitors]. |
| PubMedID- 21306252 | Everolimus and giant-cell astrocytomas in tuberous sclerosis. |
| PubMedID- 21297924 | From the bench to the bedside: everolimus for subependymal giant cell astrocytomas in tuberous sclerosis complex, optic nerve regeneration, targeted cytotoxins for gliomas. |
| PubMedID- 23743818 | Recent studies support the use of everolimus for subependymal giant cell astrocytomas associated with tuberous sclerosis and suggest it might represent a disease-modifying treatment for other aspects of tuberous sclerosis. |
| PubMedID- 23509629 | Everolimus has been approved for the treatment of papillary renal carcinoma, pancreatic neuroendocrine tumor, some types of breast cancer, and subependymal giant cell astrocytoma associated with tuberous sclerosis [8–11]. |
| PubMedID- 23231513 | Everolimus (rad001): first systemic treatment for subependymal giant cell astrocytoma associated with tuberous sclerosis complex. |
| PubMedID- 26120474 | The united states food and drug administration (fda) has approved rapamycin (sirolimus) and several rapamycin derivative compounds (“rapalogs”) that inhibit mtor for the treatment of renal cancer, subependymal giant cell astrocytoma associated with tuberous sclerosis, and neuroendocrine pancreatic tumors. |
| PubMedID- 24319280 | Objective: this study was aimed to explore parents' experience of assisting children affected by tuberous sclerosis complex (tsc) with subependymal giant-cell astrocytoma (sega) manifestation, in order to understand their caring needs and expectation of support. |
| PubMedID- 24105488 | We review the timing and use of surgery versus pharmacotherapy for the treatment of subependymal giant cell astrocytoma in patients with tuberous sclerosis complex. |
| PubMedID- 20133820 | Novel proteins regulated by mtor in subependymal giant cell astrocytomas of patients with tuberous sclerosis complex and new therapeutic implications. |
| PubMedID- 21047224 | Everolimus for subependymal giant-cell astrocytomas in tuberous sclerosis. |
| PubMedID- 23138436 | Subependymal giant cell astrocytoma associated with tuberous sclerosis presenting with intratumoral bleeding. |
| PubMedID- 25143481 | Everolimus treatment for an early infantile subependymal giant cell astrocytoma with tuberous sclerosis complex. |
| PubMedID- 25002765 | The variety of astrocytomas commonly associated with tuberous sclerosis is the sega with incidences ranging from 6% to 16%. |
| PubMedID- 24667713 | Everolimus has demonstrated substantial clinical benefit in randomized, controlled, phase iii studies leading to approval for the treatment of advanced renal cell carcinoma, advanced neuroendocrine tumors of pancreatic origin, renal angiomyolipoma and subependymal giant-cell astrocytoma associated with tuberous sclerosis complex, as well as advanced hormone-receptor-positive (hr(+)) and human epidermal growth factor receptor-2-negative advanced breast cancer. |
| PubMedID- 26248290 | Another report using everolimus as a treatment for subependymal giant cell astrocytoma associated with tuberous sclerosis complex for approximately 3 years found the most frequent adverse events were also aphthous stomatitis and respiratory infections in children under 3 years of age, and no significant neuropsychological changes were noticed between baseline and follow-up [22]. |
| PubMedID- 23391693 | Management of subependymal giant cell astrocytoma (sega) associated with tuberous sclerosis complex (tsc): clinical recommendations. |
| PubMedID- 24756805 | Everolimus has been approved by the fda and the ema for the treatment of advanced renal cell carcinoma (rcc), subependymal giant cell astrocytoma (sega) associated with tuberous sclerosis (tsc), pancreatic neuroendocrine tumors (pnet), in combination with exemestane in advanced hormone-receptor (hr)-positive, her2-negative breast cancer. |
| PubMedID- 20887114 | Rapamycin as an alternative to surgical treatment of subependymal giant cell astrocytomas in a patient with tuberous sclerosis complex. |
| PubMedID- 23489586 | Currently, the food and drug administration (fda) has approved cci-779 for the treatment of advanced renal cell carcinoma, and rad001 for the treatment of advanced renal cell carcinoma, subependymal giant cell astrocytoma (sega) associated with tuberous sclerosis complex (tsc), progressive neuroendocrine tumors of pancreatic origin, and postmenopausal women with advanced hormone-receptor-positive, her2-negative breast cancer (in combination with exemestane). |
| PubMedID- 21792104 | Mtor inhibitors in the treatment of subependymal giant-cell astrocytomas associated with tuberous sclerosis. |
| PubMedID- 24507694 | Surgical treatment of subependymal giant cell astrocytoma in tuberous sclerosis complex patients. |
| PubMedID- 23229407 | Neuro-oncology: everolimus for astrocytoma in tuberous sclerosis complex. |
| PubMedID- 21306253 | Everolimus and giant-cell astrocytomas in tuberous sclerosis. |
Page: 1 2